BR0016135A - Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto - Google Patents

Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto

Info

Publication number
BR0016135A
BR0016135A BR0016135-7A BR0016135A BR0016135A BR 0016135 A BR0016135 A BR 0016135A BR 0016135 A BR0016135 A BR 0016135A BR 0016135 A BR0016135 A BR 0016135A
Authority
BR
Brazil
Prior art keywords
particle size
compound
reduced
reduced particle
conditions associated
Prior art date
Application number
BR0016135-7A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0016135A publication Critical patent/BR0016135A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/64Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMA DE TAMANHO DE PARTìCULA REDUZIDO, USO DE UMA SUBSTâNCIA, COMPOSIçãO FARMACêUTICA, MéTODOS PARA O TRATAMENTO OU A PROFILAXIA DE CONDIçõES ASSOCIADAS COM REDUZIDA SENSIBILIDADE à INSULINA E DE DESLIPIDEMIA, DIABETES MELITO DO TIPO H, HIPERGLICEMIA, HIPERINSULINEMIA, HIPERTENSãO ARTERIAL E/OU OBESIDADE ABDOMINAL E PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". A presente invenção refere-se a uma forma de tamanho de partícula reduzido do composto ácido (S)-2-etoxi-3-[4-(2-{4-metanossulfoniloxifenil}etoxi)fenil]propanóico, como mostrado na fórmula (I) ou um seu sal farmaceuticamente aceitável ou qualquer um de seu solvato. A invenção também se refere a um método de tratamento de uma ou mais condições associadas com a Síndrome de Resistência à Insulina usando a forma de tamanho de partícula reduzido do composto, ou de um seu sal farmaceuticamente aceitável na manufatura de um medicamento para uso em uma ou mais das citadas condições. A invenção refere-se adicionalmente às composições farmacêuticas contendo a forma de tamanho de partícula reduzido do composto, ou de um seu sal farmaceuticamente aceitável, ou de um seu solvato, como um ingrediente ativo, bem como a um processo para a manufatura da forma de tamanho de partícula reduzido do composto, ou de um seu sal farmaceuticamente aceitável.
BR0016135-7A 1999-12-03 2000-11-29 Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto BR0016135A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form
PCT/SE2000/002381 WO2001040169A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid

Publications (1)

Publication Number Publication Date
BR0016135A true BR0016135A (pt) 2002-08-20

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016135-7A BR0016135A (pt) 1999-12-03 2000-11-29 Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto

Country Status (32)

Country Link
EP (1) EP1237854B1 (pt)
JP (1) JP2003515580A (pt)
KR (1) KR20020067538A (pt)
CN (1) CN1216859C (pt)
AR (1) AR029456A1 (pt)
AT (1) ATE251131T1 (pt)
AU (1) AU766036B2 (pt)
BR (1) BR0016135A (pt)
CA (1) CA2392029A1 (pt)
CO (1) CO5271736A1 (pt)
CZ (1) CZ20021839A3 (pt)
DE (1) DE60005710T2 (pt)
DK (1) DK1237854T3 (pt)
EE (1) EE200200284A (pt)
ES (1) ES2208444T3 (pt)
HK (1) HK1049324B (pt)
HU (1) HUP0203692A3 (pt)
IL (1) IL149516A0 (pt)
IS (1) IS6399A (pt)
MX (1) MXPA02005165A (pt)
MY (1) MY125099A (pt)
NO (1) NO20022591L (pt)
NZ (1) NZ518926A (pt)
PL (1) PL355372A1 (pt)
PT (1) PT1237854E (pt)
RU (1) RU2248966C2 (pt)
SE (1) SE9904413D0 (pt)
SK (1) SK7662002A3 (pt)
TR (1) TR200400003T4 (pt)
UA (1) UA73959C2 (pt)
WO (1) WO2001040169A1 (pt)
ZA (1) ZA200203797B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU752059B2 (en) 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
AU763087B2 (en) 1998-10-29 2003-07-10 Dr. Reddy's Laboratories Limited An improved process for the preparation of new antidiabetic agents
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
AU2008221673B2 (en) 2007-03-08 2013-03-28 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
ES2465216T3 (es) 2007-06-04 2014-06-05 Ben Gurion University Of The Negev Research And Development Authority Compuestos de triarilo y composiciones que comprenden los mismos
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
CZ20021839A3 (cs) 2002-08-14
SK7662002A3 (en) 2002-10-08
RU2248966C2 (ru) 2005-03-27
DE60005710D1 (en) 2003-11-06
HUP0203692A2 (hu) 2003-03-28
SE9904413D0 (sv) 1999-12-03
MY125099A (en) 2006-07-31
IS6399A (is) 2002-05-28
ES2208444T3 (es) 2004-06-16
NO20022591D0 (no) 2002-05-31
TR200400003T4 (tr) 2004-02-23
MXPA02005165A (es) 2003-09-25
UA73959C2 (en) 2005-10-17
HUP0203692A3 (en) 2005-05-30
DE60005710T2 (de) 2004-08-05
IL149516A0 (en) 2002-11-10
NO20022591L (no) 2002-05-31
HK1049324B (en) 2004-04-30
JP2003515580A (ja) 2003-05-07
PL355372A1 (en) 2004-04-19
AU766036B2 (en) 2003-10-09
EP1237854A1 (en) 2002-09-11
CA2392029A1 (en) 2001-06-07
PT1237854E (pt) 2004-02-27
AU2034801A (en) 2001-06-12
RU2002113169A (ru) 2004-01-20
AR029456A1 (es) 2003-07-02
ATE251131T1 (de) 2003-10-15
HK1049324A1 (en) 2003-05-09
WO2001040169A1 (en) 2001-06-07
ZA200203797B (en) 2003-08-13
CN1402704A (zh) 2003-03-12
EP1237854B1 (en) 2003-10-01
KR20020067538A (ko) 2002-08-22
CO5271736A1 (es) 2003-04-30
CN1216859C (zh) 2005-08-31
EE200200284A (et) 2003-08-15
DK1237854T3 (da) 2004-01-12
NZ518926A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
BR0016135A (pt) Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto
BR0016131A (pt) Forma cristalina, formulação farmacêutica, uso de uma forma cristalina, uso de uma substância, métodos para tratamento ou a profilaxia de, condições associadas com reduzida sensibilidade à insulina, e de deslipidemia, diabetes melito do tipo 2, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal, e , processo para a preparação de uma forma cristalina de um composto de fórmula i
EP0427247B1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
ES2284212T3 (es) Tratamiento de diabetes con tiazolidinadiona y metformina.
BR0211665A (pt) Composto, composição farmacêutica, método para a redução de glicose, método para a prevenção ou para tratamento de doenças, medicamento para a redução de glicose, medicamento para a prevenção ou para o tratamento de doenças, uso do composto, da composição farmacêutica e do medicamento e processo para a preparação do composto
BR0317458A (pt) EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
EA200800198A1 (ru) Способы предупреждения и лечения метаболических нарушений и новые производные пиразол-о-гликозида
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
BRPI0616324A2 (pt) formulaÇço de cÁpsula de pirfenidona e excipientes farmaceuticamente aceitÁveis
BRPI0513824A (pt) derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes
EP1256343A1 (en) Flibanserin for the treatment of extrapyramidal movement disorders
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
BRPI0111142B1 (pt) Use of derivatives of biguanide or of its pharmaceutically acceptable salts thereof for manufacture of a medicinal product having a healing effect
BRPI9913746B8 (pt) composto da série de piridínio, processo para prepará-lo, uso do mesmo, composição farmacêutica para o tratamento de complicações diabéticas e doenças relacionadas ao envelhecimento, e, métodos para a preparação de uma formulação parenteral
BRPI0407303A (pt) Composição farmacêutica
BR0317359A (pt) Uso de ácidos alfa-feniltiocarboxìlico e alfa-feniloxicarboxìlico com atividade de diminuição de glicose no soro e diminuição de lipìdios no soro
PT1704860E (pt) Derivados de benzamidina para o tratamento e prevenção da mucosite
KR20080111021A (ko) 철 대사 장애의 치료를 위한 스트로빌루린의 용도
CN1044400A (zh) 哌啶子基链烷醇衍生物的液体药物组合物
CA3046458A1 (en) Parenteral liquid preparation comprising carbamate compound
JP5052028B2 (ja) アシタザノラスト含有組成物
BR112021013582A2 (pt) Medicamento profilático ou terapêutico para doenças neurodegenerativas
JP2007509946A5 (pt)
CN113143950B (zh) 一种治疗肝病的药物组合物及其应用
KR950032191A (ko) 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.